Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more
7/1/2025
/ Centers for Medicare & Medicaid Services (CMS) ,
Drug Pricing ,
Federal Grants ,
Health Care Providers ,
HRSA ,
Inflation Reduction Act (IRA) ,
Medicaid ,
Medicaid Drug Rebate Program ,
Medicare ,
Medicare Part D ,
Most-Favored Nations ,
Pharmaceutical Industry ,
Pharmacies ,
Pharmacy Benefit Manager (PBM) ,
Prescription Drugs ,
Section 340B
Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of our Connected With Latham podcast series,...more
State-level oversight of M&A and other strategic transactions involving healthcare is continuing to expand into new markets and impact growth strategies.
The interest and need for healthcare services transactions in the...more
10/18/2024
/ Acquisitions ,
Antitrust Provisions ,
Federal Trade Commission (FTC) ,
Hart-Scott-Rodino Act ,
Health Care Providers ,
Healthcare Facilities ,
Hospital Mergers ,
Hospitals ,
Merger Agreements ,
Merger Controls ,
Mergers
Companies should prepare for increased regulatory scrutiny into healthcare transactions and increased emphasis on compliance programs.
The Federal Trade Commission (FTC), the Department of Justice (DOJ), and the...more